News | November 12, 2019

Aptinyx Initiates Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions 200-patient painful diabetic peripheral neuropathy study and 300-patient fibromyalgia study build on previous compelling data obtained in these indications Top-line...

News | October 28, 2019

Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting Study met primary and secondary endpoints – statistically significant effects on neuroimaging...

News | June 26, 2019

Aptinyx Presents Preclinical Data Demonstrating Robust Activity of NYX-783 on Alcohol-Seeking Behavior and Relapse-Like Behavior in Multiple Models of Alcohol Use Disorder EVANSTON, Ill., June 26, 2019 (GLOBE NEWSWIRE) — Aptinyx Inc. (Nasdaq: APTX), a...

News | June 10, 2019

Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain NYX-2925 demonstrated statistically significant effects on a range of neuroimaging...